Donald P McDonnell Selected Research

Neoplasms (Cancer)

6/2022	Estrogen receptor signaling in the immune system.
12/2021	Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.
12/2021	Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.
1/2021	Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer.
1/2021	Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells.
1/2020	The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor.
1/2020	Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
10/2019	The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.
1/2019	Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.
1/2019	Inhibition of ERRα Prevents Mitochondrial Pyruvate Uptake Exposing NADPH-Generating Pathways as Targetable Vulnerabilities in Breast Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Donald P McDonnell Research Topics

Disease

55	Neoplasms (Cancer) 06/2022 - 01/2005
48	Breast Neoplasms (Breast Cancer) 12/2021 - 03/2002
21	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 04/2002
11	Neoplasm Metastasis (Metastasis) 01/2021 - 09/2009
5	Osteoporosis 01/2019 - 07/2002
3	Hypercholesterolemia 10/2017 - 03/2013
3	Triple Negative Breast Neoplasms 01/2017 - 04/2016
3	Inflammation (Inflammations) 01/2015 - 08/2007
2	Melanoma (Melanoma, Malignant) 12/2021 - 12/2014
2	Obesity 10/2017 - 09/2014
2	Disease Progression 01/2017 - 01/2013
2	Heart Failure 09/2014 - 01/2011
2	Macular Degeneration (Age-Related Maculopathy) 10/2013 - 02/2011
2	Metabolic Diseases (Metabolic Disease) 08/2010 - 12/2007
2	Cardiovascular Diseases (Cardiovascular Disease) 04/2009 - 10/2008
1	Autoimmune Diseases (Autoimmune Disease) 06/2022
1	Disease Resistance 12/2021
1	Carcinoma (Carcinomatosis) 01/2017

Drug/Important Bio-Agent (IBA)

20	Estrogens (Estrogen)FDA Link 06/2022 - 01/2005
20	Estrogen ReceptorsIBA 12/2021 - 11/2008
19	Androgen Receptors (Androgen Receptor)IBA 01/2018 - 11/2003
17	AndrogensIBA 01/2018 - 04/2002
12	Selective Estrogen Receptor Modulators (SERM)IBA 01/2020 - 07/2002
11	Proteins (Proteins, Gene)FDA Link 10/2019 - 03/2009
10	LigandsIBA 10/2019 - 04/2002
9	CholesterolIBA 01/2021 - 01/2008
9	Tamoxifen FDA LinkGeneric 11/2015 - 05/2005
8	Fulvestrant (Faslodex)FDA Link 12/2021 - 10/2007
8	Hormones (Hormone)IBA 01/2019 - 05/2004
8	27-hydroxycholesterolIBA 10/2017 - 08/2010
8	EnzymesIBA 10/2017 - 09/2008
7	Estrogen Receptor alphaIBA 10/2019 - 03/2002
7	ERRalpha Estrogen-Related ReceptorIBA 01/2019 - 12/2006
7	Aromatase InhibitorsIBA 01/2019 - 12/2005
7	Pharmaceutical PreparationsIBA 01/2019 - 12/2010
5	Androgen Antagonists (Antiandrogens)IBA 10/2016 - 04/2002
4	Transcription Factors (Transcription Factor)IBA 12/2021 - 05/2010
4	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 03/2009
3	enzalutamideIBA 01/2018 - 10/2016
3	OxysterolsIBA 10/2017 - 03/2013
3	Progesterone Receptors (Progesterone Receptor)IBA 01/2017 - 04/2010
3	LipidsIBA 01/2017 - 02/2011
3	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2015 - 02/2010
3	Small Interfering RNA (siRNA)IBA 07/2012 - 11/2008
3	Messenger RNA (mRNA)IBA 04/2010 - 03/2009
2	Immune Checkpoint InhibitorsIBA 06/2022 - 12/2021
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2019
2	A-Form DNA (A-DNA)IBA 01/2021 - 05/2010
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2020 - 11/2015
2	Calcium-Calmodulin-Dependent Protein Kinase KinaseIBA 01/2019 - 01/2011
2	Pyruvic Acid (Pyruvate)IBA 01/2019 - 12/2006
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 04/2016
2	Androgen Receptor AntagonistsIBA 01/2018 - 07/2009
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2017 - 01/2017
2	Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)IBA 06/2017 - 01/2017
2	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 06/2017 - 11/2013
2	bicalutamide (Casodex)FDA LinkGeneric 10/2016 - 07/2009
2	hydroxyflutamideIBA 10/2016 - 07/2009
2	Indicators and Reagents (Reagents)IBA 04/2016 - 04/2009
2	CopperIBA 06/2015 - 10/2014
2	Disulfiram (Antabuse)FDA Link 06/2015 - 10/2014
2	Liver X ReceptorsIBA 11/2013 - 02/2011
2	Aromatase (CYP19)IBA 05/2013 - 07/2011
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 02/2011 - 04/2005
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 02/2011 - 08/2007
2	Orphan Nuclear ReceptorsIBA 11/2010 - 11/2008
2	Estrogen Receptor Modulators (Antiestrogen)IBA 10/2007 - 01/2005
2	3- (4- (1,2- diphenylbut- 1- enyl)phenyl)acrylic acidIBA 10/2007 - 05/2005
1	LasofoxifeneIBA 01/2020
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2020
1	Blocking AntibodiesIBA 10/2019
1	Humanized Monoclonal AntibodiesIBA 10/2019
1	NADP (NADPH)IBA 01/2019
1	Oxygen (Dioxygen)IBA 01/2019
1	ChemokinesIBA 01/2019
1	mahuang-tangIBA 01/2019
1	Sex Hormone-Binding GlobulinIBA 01/2019
1	25-hydroxyvitamin DIBA 01/2019
1	LSZ102IBA 12/2018
1	histone deacetylase 3IBA 01/2018
1	Vorinostat FDA Link 01/2018
1	Histone Deacetylase InhibitorsIBA 01/2018
1	Proteolysis Targeting ChimeraIBA 01/2018
1	snake venom protein C activatorIBA 01/2018
1	RGFP966IBA 01/2018
1	abirateroneIBA 06/2017
1	seviteronelIBA 06/2017
1	human ERBB2 proteinIBA 01/2017
1	Trastuzumab (Herceptin)FDA Link 01/2017
1	Lapatinib (GW572016)FDA Link 01/2017
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2017
1	Sterol Regulatory Element Binding Protein 2IBA 01/2017
1	LDL Receptors (LDL Receptor)IBA 01/2017
1	Atorvastatin (Lipitor)FDA Link 01/2017
1	Docetaxel (Taxotere)FDA Link 01/2017

Therapy/Procedure

31	Therapeutics 12/2021 - 05/2004
6	Drug Therapy (Chemotherapy) 01/2021 - 09/2008
4	Castration 01/2018 - 10/2016
1	Immunotherapy 01/2019
1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2019